reports
Update: Awaiting future catalysts
Can-Fite’s lead compound CF101 is continuing to advance in a Phase II/III study in psoriasis, with top-line data now expected in Q115. The company is also working on finalising a Phase III protocol for this candidate in rheumatoid arthritis (RA), although we continue to anticipate a partnership will be necessary before starting such a trial. Our new $88m rNPV (vs $90m previously) reflects minor adjustments in the timing of potential market introductions in RA and psoriasis, and continues to re...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.